SciSparc Ltd.’s subsidiary NeuroThera Labs Inc. has filed a U.S. patent application for a combination therapy pairing MDMA with N-acylethanolamines, including palmitoylethanolamide, aimed at treating post-traumatic stress disorder, anxiety and eating disorders.
The application, published by the United States Patent and Trademark Office, reflects NeuroThera’s ongoing collaboration with Clearmind Medicine Inc., which has produced 13 published patent applications globally. Embodiments in the filing describe potential enhancements to therapeutic potency, adjustments to dosing requirements and mitigation of side effects by combining the compounds.
NeuroThera, a clinical-stage pharmaceutical company focused on central nervous system disorders, is developing programs that include cannabinoid-based treatments for Tourette syndrome, Alzheimer’s disease, autism spectrum disorder and status epilepticus. SciSparc holds NeuroThera as a subsidiary.
The patent filing follows the U.S. Food and Drug Administration’s July 14 finalization of guidance titled Psychedelic Drugs: Considerations for Clinical Investigations. The document classifies MDMA as a psychedelic drug and outlines challenges in clinical development due to its psychoactive effects, including shifts in mood, cognition and perception. It also provides recommendations on trial design, subject safety, data collection and new drug application requirements for psychedelic-based therapies.
